Monday, February 27, 2017

Alchemist enters option to buy claims in Quebec

2017-02-27 09:32 ET - News Release


Mr. Keith Anderson reports
ALCHEMIST MINING SIGNS LOI TO PURCHASE GROUND STRATEGICALLY LOCATED ADJACENT TO OSISKO MINING, WINDFALL LAKE AREA, QUEBEC
Alchemist Mining Inc. has entered into a binding letter of intent with arm's-length vendors whereby Alchemist has the exclusive right to acquire a 100-per-cent interest in and to claims, consisting of 2,210.91 hectares, located adjacent to Osisko Mining's Windfall Lake gold property in the Urban Barry belt, Quebec.

The area has generated a lot of recent headlines. Beaufield Resources reported in a news release dated Feb. 8, 2017, that Osisko's Windfall property has a 400,000-metre drilling program under way. In the month of February, collectively, Beaufield, Osisko, Bonterra Resources and Metanor Resources announced an aggregate of almost $79-million in proposed financings, almost $66-million of which were bought deals.

President of Alchemist, Keith Anderson, stated: "The Windfall Lake gold camp will be receiving a large amount of exploration work, especially with Osisko's 400,000-metre drill program. Alchemist is very excited to have secured ground in the area due to the favourable geology and the possibility of the regional gold discoveries being pervasive throughout the region."
In order to earn a 100-per-cent interest in the property, the company must pay $2,500 and issue an aggregate of 800,000 common shares upon the closing of a definitive agreement. The common shares will be subject to a four-month-and-one-day hold period.
We seek Safe Harbor.

Saturday, February 25, 2017

Scorpion venom drink?

Carrara to acquire B.C. health company in RTO

2017-02-17 11:14 ET - News Release

Mr. Robert Coltura reports
CARRARA SIGNS LETTER OF INTENT TO ACQUIRE PREVECEUTICAL MEDICAL
Carrara Exploration Corp. has signed a non-binding letter of intent with PreveCeutical Medical Inc. (PMI), whereby the company will acquire all of the issued and outstanding common shares in the capital of PMI from the PMI shareholders in exchange for common shares without par value in the capital of the company by way of a share exchange or amalgamation or other transaction, which will constitute a reverse takeover of the company by PMI. Upon the closing of the transaction, PMI will be a wholly owned subsidiary of the company, and the selling shareholders will control a majority of the issued and outstanding voting securities of the company.

About PMI
PMI is a private British Columbia-based health and wellness company focused on utilizing nature and science for the benefit of health-conscious consumers. PMI currently has one product available for sale, the CELLB9 immune-system booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide, obtained from blue scorpion serum. The active potentiated ingredients in the blue scorpion serum appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.

PMI's market strategy approach is focused on two quick-to-market product lines derived from Caribbean blue scorpion venom, while undertaking an accelerated preclinical research program to isolate and synthesize the venom's critical properties, as described in the following:

  1. 1CELLB9 immune-system booster -- PMI intends to move forward with its Internet sales strategy for CELLB9. PMI has commenced its Health Canada application for an NPN (natural product number) and is also undertaking nutraceutical/holistic medicine registrations for the United States and European Union.
  2. Energy drink development -- PMI intends to develop a special formulation of polarized scorpion venom in three therapeutic energy drinks. PMI is in product development and plans to launch the beverages in North America in 2017.
  3. Preclinical evaluation -- PMI intends to conduct a 36-month preclinical evaluation program to be led by Dr. Makarand Jawadekar, PMI's chief science officer, which is anticipated to cover the following subjects:
    • Assessment of currently available research data on nature identical peptides;
    • Synthesis of targeted peptides and their stability assessment;
    • Propose target product profile (TPP) for IND (investigational new drug) dosage form;
    • The filing of an IND submission with the U.S. Food and Drug Administration. The IND program is the means by which the corporation obtains permission to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved the by the FDA.
PMI's goal is to develop an extensive patent portfolio and position specific synthesized peptide(s) for IND and phase 1 clinical trials in partnership with established pharmaceutical industry participants. Phase 1 is the phase where researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range and identify side effects.
Proposed transaction

Carrara proposes to acquire all of the issued and outstanding common shares of PMI on the basis of one Carrara share for each PMI share, with the result that, excluding the private placement (as defined below) and any other financings that may be carried out by Carrara or PMI, upon the completion of the consolidation (as defined below) and the closing of the transaction, the selling shareholders will hold approximately 91 per cent (non-diluted basis) of the issued and outstanding common shares in the capital of the company. The transaction would also result in the exchange of each option and/or warrant held by PMI optionholders and warrantholders (if any) with options and/or warrants issued by the company of like tenor as those of the PMI options and warrants so exchanged.

The closing of the transaction is subject to a number of conditions including, but not limited to, completion of satisfactory due diligence by both PMI and the company, approval of the transaction by the respective boards of directors and shareholders of the company and PMI, the company and PMI entering into a definitive agreement regarding the transaction, the completion of the consolidation, the closing of the private placement, and the company obtaining applicable regulatory approvals, including the approval of the Canadian Securities Exchange for the listing of the common shares of the resulting issuer (as defined below). There can be no assurance that the transaction will be completed as proposed or at all.

Prior to February, 2017, the company was engaged in the business of mineral exploration and the acquisition of mineral property assets in British Columbia. Its objective was to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Boomerang property under the terms of a property option agreement dated Dec. 15, 2014. The property option agreement provides that the company may abandon the option thereunder (and the agreement) by notice in writing to the optionors and will be responsible for ensuring that the property has sufficient assessment credits recorded against it at the date of termination to keep it in good standing for a minimum of one year from the date of termination.

Upon the closing of the transaction, the company will continue the business of PMI under the name PreveCeutical Medical Inc. (the resulting issuer), or such other name as is acceptable to the B.C. registrar of companies and the CSE.

Changes in management
Upon completion of the transaction, it is anticipated that Matthew Coltura will remain on the board of directors of the resulting issuer, and the management of the resulting issuer will include the following individuals.

Stephen Van Deventer, chairman and chief executive officer
Mr. Van Deventer is an experienced businessman, corporate director and co-owner of Cornerstone Global Partners Inc. Specializing in international corporate relations and business development over the last 25 years. Mr. Van Deventer has focused on launching small- to medium-sized companies into the public markets in Canada, the United States and Europe. He has also owned and operated private companies.

Kimberly Van Deventer, president and director
Ms. Van Deventer is an entrepreneur with a successful record of accomplishment that she brings to PreveCeutical, and she is co-owner of Cornerstone Global Partners. Motivated and determined, she was ranked the third-highest-grossing female business owner in British Columbia in 2009. Ms. Van Deventer is a driving force behind the business and is unwavering in her commitment to bring awareness of health and disease prevention to people everywhere.

Brian Harris, vice-president of corporate development and director
Mr. Harris is the managing partner at Marketing Services International, a consulting company that provides professional services to early-stage private and public companies with a focus on science-based new functional food and natural health products. Mr. Harris is a director and interim CEO of MedAgri Marihuana Labs Inc., a private company that has made an application for medical marijuana producer's licence with Health Canada. Mr. Harris also served as a director and CEO of Russell Breweries Inc., a TSX Venture Exchange-listed company. During his 10-year tenure, Russell was one of the fastest-growing companies in Canada. Prior to that, Mr. Harris was a director and senior vice-president for EFTech Ltd., a public company listed on the Australian Securities Exchange and a leading supplier of electronic funds transfer services at the point of sale in Australia. He was also a founder of BASS (Best Available Seating Service) International, the computer ticketing system, which operated in 12 markets and four continents, now known as TicketMaster. In the mid-1980s Mr. Harris was the founder and president of SmokeFree Pty. Ltd. in South Africa. SmokeFree helped people stop smoking without gaining weight using a proprietary nutritional supplement three times a day and participating in a support group. During that period, SmokeFree became the leading company in the smoking-cessation market in that country.

Greg Reid, director
Mr. Reid is a filmmaker, a keynote speaker, as well as a No. 1 best-selling author, entrepreneur and the CEO of several successful corporations, who has dedicated his life to helping others achieve the ultimate fulfilment of finding and living a life of purpose. In addition to being published in over 35 books and featured on nationally syndicated programs across the United States, he is also the creator and producer on the international-acclaimed films Pass It On and Three Feet From Gold.

Shabira Rajan, CPA, CGA, chief financial officer and controller
Ms. Rajan is the owner of SHROF Financial Management and Accounting, providing financial management services to clients. Prior to that, Ms. Rajan was the director of finance for Canada Line Rapid Transit Inc., a $2-billion P3 (public-private partnership) infrastructure project where she was responsible for all financial aspects of the project, including strategies for cash management, regulatory and contractual compliance and reporting, budgeting, forecasting, analysis, procurement, implementation of policies and procedures, and IT. Ms. Rajan is a chartered professional accountant and holds an MBA from Laurentian University and an advanced specialty certificate in forensic science technology, forensic and investigative accounting option, from the British Columbia Institute of Technology. She was a project management professional and an associate member of the Institute of Chartered Secretaries and Administrators. She recently completed the "executive leadership -- developing sustainable non-profit organizations in the 21st century" program with the City University of Seattle. Ms. Rajan has served as a board member with WAVAW (Women Against Violence Against Women) and was the chair, education and recruiting, with the Richmond/South Delta chapter of CGA BC.

Dr. Makarand Jawadekar, chief science officer
Since 2010, Dr. Jawadekar has been the owner of Melinda Consulting LLC, a pharmaceutical consulting company. Prior to Melinda Consulting, Dr. Jawadekar worked at Pfizer Inc. in Groton-New London, Conn., for 28 consecutive years, more recently as a director of portfolio management. He was responsible for the drug delivery technology assessment function involving external drug delivery technologies. Dr. Jawadekar has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his PhD in pharmaceutics at the University of Minnesota.

Nicole Goncalves-Krysinski, chief legal officer
Ms. Goncalves-Krysinski is an attorney and a partner in her own law firm in New York. She has at JD from St. John's University and BA from University of California, Los Angeles. Ms. Goncalves-Krysinski practises in both state and federal courts handling a wide range of cases, including complex bankruptcy matters and matrimonial and criminal defence litigation. Her areas of practice also include contract negotiations, business and transactional law, and corporate advisement. She is an independent contractor to the corporation.

Alicia Rebman, vice-president, marketing and advertising
Ms. Rebman is a marketing professional with a background in publishing technologies, communications and graphic design with a specialty in branding and communications for social enterprise and NGO (non-governmental organization) start-ups. Ms. Rebman ran a successful design services company for six years and then elevated to head the marketing department for the global office of Hartley & Marks Group, an international design and publishing company.
Share consolidation Prior to the closing of the transaction, the company will complete a consolidation of all of its issued and outstanding common shares without par value on the basis of three old Carrara shares for one new Carrara share.

Any fractional shares resulting from the consolidation will be rounded up to the next whole share if such fractional share was equal to or greater than one-half of a share, and rounded down to the next whole share if such fractional share was less than one-half of a share.
The consolidation will result in the amount of issued and outstanding Carrara shares being reduced from 11,987,000 shares to approximately 3,995,667 issued and outstanding shares. In connection with the consolidation, issued and outstanding options and warrants exchangeable for Carrara shares shall be adjusted in accordance with the terms and conditions of such options and warrants.
Registered shareholders will receive a letter of transmittal from Computershare Investor Services Inc. describing the process by which shareholders may obtain new certificates representing their postconsolidation Carrara shares. Carrara shares held in uncertified form by non-registered shareholders through brokerage accounts will be converted through each shareholder's brokerage accounts. Non-registered shareholders should consult their broker for further information.

Private placement
Subsequent to the consolidation and in conjunction with the transaction, Carrara will undertake a non-brokered private placement of up to 10 million units for minimum gross proceeds of $1-million and maximum gross proceeds of $5-million. Each unit will be issued at a price of 50 cents per unit and consist of one Carrara share and one transferable common share purchase warrant. Each warrant will entitle the holder thereof to acquire one Carrara share at an issue price of $1 per share for a period of 12 months from the closing of the private placement, provided that in the event that the closing price of the Carrara shares trading on the CSE is at least $1.50 or more for 10 consecutive business days, the company shall have the option of accelerating the expiration date for the exercise of the warrants by giving at least 14 business days notice.

The proceeds realized from the private placement will be held in escrow until the closing of the transaction and the listing of the resulting issuer's common shares on the CSE. The proceeds will then be available for general corporate and working capital purposes by the resulting issuer.
The company may pay finders' fees to certain persons equal to 8 per cent of the gross proceeds raised in the private placement from subscribers introduced to the company by such persons, which fees shall be payable in cash, units or a combination of both, at the discretion of the company.
Loan

In connection with the transaction, Mr. Van Deventer will loan to the company $30,000 for the purpose of covering certain legal fees (and the taxes and disbursements associated therewith) that the company will incur as part of the transaction. Upon completion of the transaction, the company shall fully repay the loan to the Mr. Van Deventer without any set-off or deductions, with any unpaid amount being converted to common shares of the resulting issuer at the closing price of such shares on the previous trading day on the CSE.

Further information
Further details about the transaction will be provided in the disclosure document to be prepared and filed in respect of the transaction on the company's SEDAR profile.
We seek Safe Harbor.